Lower Merion Neurology Research Foundation
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
After obtaining informed consent, patients enrolled in the 'study drug' arm of the trial will receive Ketamine (1 mg/ml solution prepared in normal saline) infusion at a rate of 20 mg/h for a period of 24 hours. The infusion will start at a rate of 5 mg/h, and then gradually tapered up during the first 3 hours by 5 mg an hour. Similarly, the infusion rate will be gradually tapered down at a rate of 5 mg/h during the last 3 hours of infusion. The patients randomized to the 'placebo arm' of the trial will receive normal saline infusion at the same rates. In order to prevent the psychogenic adver…
Inclusion Criteria: 1. All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time 2. An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate 3. Pre-stroke modified Rankin scale of 0-2 4. Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy. Exclusion Criteria: 1. Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy 2. Longer than 24 hours since last known well time…
IV infusion
IV infusion
Injection
Arctuva estimate
Verify or correct the compensation shown for this listing.